CD19 and cancer: A Phase 1 and 2 clinical trial (NCT03056339) involving the injection of CD19 CAR-NK cells into 11 patients with relapsed or refractory CD19-positive cancers demonstrated that this therapy was effective in most patients without any apparent secretion of inflammatory cytokines such as IL-1 or IL-6.